Clinical trials: Blood Cancers, active
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
A Non-interventional Study of Participants With BPDCN Treated With Chemotherapy
The main goal of this study is to investigate the effectiveness and safety of chemotherapy agents in the treatment of participants with BPDCN and to provide comparator arm data to the prospective ELZONRIS registry study…
- Trial name
- NCT07785180
- Testing
- Chemotherapy
- Where
- 67 sites in Denmark, France and 9 more
- Volunteers
- 140 people
- Sponsor
- Stemline Therapeutics, Inc.
Multiple Myeloma, Smoldering Multiple Myeloma
A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM)
The purpose of this study is to determine the efficacy of treating patients with intermediate risk smoldering multiple myeloma (SMM) with combinational therapy with dexamethasone and lenalidomide (Rd) and patients with high risk…
- Trial name
- iStopMM (NCT03815279)
- Testing
- Carfilzomib, Lenalidomide, Dexamethasone
- Where
- Iceland
- Volunteers
- 80 people
- Sponsor
- Landspitali University Hospital
Multiple Myeloma, Immune System Diseases
Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma
The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancer. This research study combines two different ways of fighting disease: antibodies and T cells.
- Trial name
- NCT03672318
- Testing
- CAR138 T Cells
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Haemophilia A (Moderate or Severe), Hemophilia, Classic
A Study to Investigate the Course of Synovial Hypertrophy in Patients With Haemophilia A on Efanesoctocog Alfa Prophylaxis
The rationale for conducting this open-label phase 4 study is to assess whether once-weekly prophylaxis with efanesoctocog alfa (50 IU/kg) improves the disease course of existing synovial hypertrophy and prevents the risk of…
- Conditions
- Haemophilia A (Moderate or Severe), Hemophilia, Classic, Haemophilia, Hemophilia
- Trial name
- NCT06752850
- Testing
- Efanesoctocog alfa
- Where
- 10 sites in Italy, Norway and 2 more
- Volunteers
- 37 people
- Sponsor
- Swedish Orphan Biovitrum
Chemotherapy-Induced Peripheral Neuropathy, Hematopoietic and Lymphoid Cell Neoplasm
Testing the Effects of Exercise on Chemotherapy-Induced Peripheral Neuropathy
This phase II trial studies whether using exercise is better than the usual approach for treating chemotherapy-induced peripheral neuropathy (CIPN).
- Conditions
- Chemotherapy-Induced Peripheral Neuropathy, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
- Trial name
- CIPN (NCT04888988)
- Testing
- Best Practice, Exercise Counseling, Exercise Intervention
- Where
- 93 sites in United States
- Volunteers
- 133 people
- Sponsor
- University of Rochester NCORP Research Base
Multiple Myeloma or Plasmacytoma
Engineered Dendritic Cell Vaccines for Multiple Myeloma
The purpose of this study is to determine the feasibility, safety, and efficacy of dendritic cell (DC) vaccines in the treatment of multiple myeloma (MM) or plasmacytoma based on immune-modified DC vaccines (DCvac).
- Trial name
- NCT06435910
- Testing
- DC vaccines
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
Multiple Myeloma, Fall Risk Factors
Fall Risk Assessment and an Exercise Intervention for Prevention of Falls in Multiple Myeloma Patients
Approximately one third of the population over the age of 65 falls at least once a year. The risk of falling is in increased in older patients with tumor diseases.
- Conditions
- Multiple Myeloma, Fall Risk Factors, Strength Training Effects, Balance Training Effects
- Trial name
- Myfall (NCT07044427)
- Testing
- Strength and balance training in combination with a treadmill-based pertubation intervention
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- University Hospital Heidelberg
Multiple Myeloma
P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma
Phase 1 study comprised of open-label, dose escalation, multiple cohorts of P-BCMA-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells in subjects with relapsed / refractory Multiple Myeloma (RRMM).
- Trial name
- MM (NCT04960579)
- Testing
- P-BCMA-ALLO1 CAR-T cells, Rimiducid, Methotrexate
- Where
- 23 sites in United States
- Volunteers
- 275 people
- Sponsor
- Poseida Therapeutics, Inc.
Thrombocytopenia
Time-limited Treatment With Avatrombopag Pre- and Post-CAR T-cell Therapy to Prevent Post-CAR T-cell Cytopenias
The purpose of this study is to study how avatrombopag (the study drug) may prevent certain side effects in adults with lymphoma and myeloma getting cancer treatment (CAR-T cell therapy).
- Trial name
- CAR-T 002 (NCT07895017)
- Testing
- Avatrombopag
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of Virginia
Hematologic Malignancy
Cancer and Immune Cell Metabolism in Patients With Hematological Malignancies
This study investigates how metabolism in cancer and immune cells shapes the bone marrow environment, influences therapy resistance, and affects outcomes in hematological malignancies.
- Trial name
- NCT07189117
- Where
- Switzerland
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Hematopoietic and Lymphoid Cell Neoplasm
Social Relationships and Accelerated Aging in Hematopoietic Cell Transplant Survivors
This project aims to elucidate the important protective elements of social relationships and identify concrete, modifiable behavioral factors that contribute to biological and phenotypic aging in hematopoietic cell…
- Trial name
- NCT04892823
- Testing
- Biospecimen Collection, Electronic Health Record Review, Questionnaire Administration
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Medical College of Wisconsin
B-cell Non Hodgkin Lymphoma
Clinical Study of Cord Blood-derived IL-10/IL-15 CD19-CAR NK in the Treatment of Refractory/Relapsed B-cell NHL
To study the safety and effectiveness of cord blood-derived IL-10/IL-15 CD19-CAR NK in patients with B-cell non-Hodgkin's lymphoma
- Trial name
- NCT06707259
- Testing
- anti-CD19 IL10/IL15 CAR-NK
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Hematological Malignancy
HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib
Now haplo stem cell transplant using bone marrow or peripheral blood is becoming more feasible with better regimens to prevent graft versus host disease (GVHD) like post transplant cyclophosphamide , tacrolimus, mycophenolate .
- Trial name
- NCT03850366
- Testing
- Bortezomib
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Henry Ford Health System
Small-cell Lung Cancer
SCLC Tarlatamab Blood Collection
The overall objective of this project is to prospectively collect blood samples throughout treatment with tarlatamab in patients with small cell lung cancer (SCLC).
- Trial name
- NCT07468656
- Volunteers
- 25 people
- Sponsor
- Duke University
Multiple Myeloma, Primary Plasma Cell Leukemia
Study of CT071 Injection in RRMM or PPCL
A Clinical Trial to Explore the Safety and Efficacy of CT071 injection in Patients with Relapsed/Refractory Multiple Myeloma or Primary Plasma Cell Leukemia
- Trial name
- NCT05838131
- Testing
- Experimental: CAR-T cells Infusion
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai Changzheng Hospital
Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma (CTCL)
A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies
Evaluate the Safety, Pharmacokinetics and Efficacy of CHT101 in Subjects With Relapsed or Refractory T or B Cell Hematological Malignancies
- Conditions
- Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma (CTCL), NHL (Non-Hodgkin Lymphoma)
- Trial name
- COURAGE (NCT06914037)
- Testing
- CHT101
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Multiple Myeloma
MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma
This study will test the safety of the study treatment, MCARH109, at different doses, to see which dose is safest in people, and to look for any good and bad effects of this treatment.
- Trial name
- NCT04555551
- Testing
- Infusion of MCARH109 T cells
- Where
- 7 sites in United States
- Volunteers
- 17 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Intracranial Hemorrhage, Hypertensive, Craniotomy Tumor Removal Surgery
Comparison of Post-Craniotomy Blood Pressure Targets
The goal of this pragmatic clinical trial is to learn if a more intensive or more liberal blood pressure target after surgery is more effective in improving patient outcomes for adults undergoing craniotomy for removal of a brain…
- Trial name
- COMPETE (NCT07093151)
- Testing
- Target SBP <160mmHg, Target SBP <140 mmHg
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Vanderbilt University Medical Center
Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia
Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes
This phase II trial studies how well donor umbilical cord blood transplant with ex-vivo expanded cord blood progenitor cells (dilanubicel) works in treating patients with blood cancer.
- Conditions
- Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid Cell Neoplasm
- Trial name
- NCT03399773
- Testing
- Dilanubicel, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Fred Hutchinson Cancer Center
Osteoporosis, Multiple Myeloma
A Study of Romosozumab in Women With Multiple Myeloma and Osteoporosis
The purpose of this study is to measure the effect of romosozumab on bone formation and breakdown (resorption) and determine if romosozumab is a safe treatment for osteoporosis and myeloma-related bone disease (MBD) in…
- Trial name
- NCT05775094
- Testing
- Romosozumab
- Where
- 7 sites in United States
- Volunteers
- 10 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.